Skip to content

Efficacy of polyherbal combination Guggulu, Guduchi, Manjistha in the management of Vatarakta (hyperuricemia)

A comparative clinical study between polyherbal combination (Guduchi, Guggulu, Manjistha) and xanthine oxidase inhibitor in the management of Vatarakta w.s.r to hyperuricemia - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072046
Enrollment
60
Registered
2024-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Sponsors

Government of West Bengal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient having classical signs and symptoms of Vatarakta mentioned in Ayurvedic text like Ruk(pain), Toda (pricking pain), Sparsha asahatva(tenderness), Shopha (swelling), Raga(redness), Daha (burning sensation) and Stabdhata(stiffness) of sandhis of pada and hasta 2.Serum uric acid level IN Female- more than 6mg/dl but less or equal 9mg/dl IN Male -more than 7mg/dl but less or equal 10mg/dl 3.Patients who agreed to follow the study protocol and give constant for clinical trial.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from diabetes mellitus and uncontrolled hypertension,malignant disorders, genetic disorders, renal disorders. 2.Any other inflammatory joint disorders like rheumatoid arthritis, tubercular arthritis, septic arthritis, psoriatic arthritis 3.Patients having deposition of monosodium urate monohydrate crystals in joints or having tophi. 4.Pregnant woman and lactating mother suffering from arthritis. 5.Severe deformity and ankylosing of the joints. 6.Patients who are not willing to come under trial or give consent.

Design outcomes

Primary

MeasureTime frame
serum uric acid level in female less than 6 mg/dl in male less than 7mg/dlTimepoint: 60 days

Secondary

MeasureTime frame
TO PREVENT URATE CRYSTAL (TOPHI) FORMATIONTimepoint: 60 DAYS

Countries

India

Contacts

Public ContactPREYOSI GHORUI

The west bengal university of health sciences

dr.tapasbhaduri@gmail.com9836362763

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026